UK NICE · December 24, 2025

NICE approves bevacizumab biosimilars for advanced bowel cancer

Original title: Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars

NICE has approved bevacizumab biosimilars for reimbursement in England for advanced bowel cancer treatment.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement UK PharmaceuticalsReimbursement

More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.

Read the official source ↗

Published by UK NICE. HealthSignal links to the original document; the summary above is extracted from the source text.